Verapamil and St. John's Wort: Can You Take Them Together?

High — Consult Your Doctorconflict
Learn about each ingredient:VerapamilSt. John's Wort

Quick answer

St. John's wort is a potent inducer of intestinal CYP3A4 and P-glycoprotein. In a controlled study, two weeks of St. John's wort reduced the AUC of R- and S-verapamil by roughly 78-80%, dramatically lowering systemic drug exposure and likely therapeutic effect.

Do not combine St. John's wort with verapamil. If you are starting verapamil for blood pressure, arrhythmia, or migraine prevention, stop St. John's wort and allow at least two weeks for the enzyme induction to wash out before relying on verapamil's effect. Tell your prescriber if you have used St. John's wort recently.

What happens when you take verapamil with St. John's wort?

Verapamil is a non-dihydropyridine calcium channel blocker used for hypertension, angina, supraventricular tachyarrhythmias, and migraine prevention. It is heavily metabolized by CYP3A4 in the gut wall and liver, with only a small fraction of an oral dose escaping first-pass elimination to reach the bloodstream. Anything that revs up CYP3A4 production will gut its bioavailability.

St. John's wort (Hypericum perforatum) is a popular over-the-counter herbal used for low mood and mild depression. Its main active constituent, hyperforin, activates a nuclear receptor called PXR (pregnane X receptor), which in turn ramps up expression of CYP3A4 and the drug-efflux pump P-glycoprotein in the intestine and liver. The induction effect builds over about 10 to 14 days and persists for a similar period after stopping the herb.

A controlled study published in Clinical Pharmacology & Therapeutics measured what happens when healthy volunteers took St. John's wort for 14 days alongside verapamil. The result was dramatic: the area under the curve (AUC) of R-verapamil dropped by 78 percent and S-verapamil by 80 percent. Peak concentrations fell substantially as well. The drug was still being absorbed normally; it was being chewed up by the newly upregulated CYP3A4 in the gut wall before it could enter the systemic circulation.

Why is this important?

An 80 percent reduction in verapamil exposure essentially erases its therapeutic effect. If you are taking verapamil to control atrial fibrillation rate, you could see your heart rate climb back into uncontrolled territory. If you are taking it for high blood pressure, your pressure may drift up. If you are using it for cluster or migraine prevention, the protective effect can disappear. Most worrying is the situation where a patient is stable on verapamil, adds St. John's wort without telling their prescriber, and then experiences a breakthrough event — an arrhythmia, a hypertensive episode, or recurrent migraines — that gets misattributed to disease progression rather than to the herb.

The reverse situation is just as concerning: a patient on St. John's wort who is started on verapamil may appear to be a non-responder, leading the prescriber to push the dose higher and higher. If the patient then stops St. John's wort, CYP3A4 levels return to normal over 10 to 14 days, and the now-too-high verapamil dose can produce dangerous bradycardia or AV block.

What should you do?

Do not take St. John's wort and verapamil together. If you want to try St. John's wort for mood, discuss it first with the prescriber managing your verapamil and consider an alternative for your heart or migraine condition while you do so. If you are starting verapamil and have been taking St. John's wort, stop the herb and wait at least two weeks before the prescriber titrates verapamil to its effective dose. Tell your prescriber every time you start, stop, or change herbal supplements — St. John's wort is just one of many CYP3A4 inducers.

If you must continue both for some reason, expect to need substantially higher verapamil doses, and accept the safety implications of withdrawal: stopping St. John's wort while continuing the increased verapamil dose risks toxicity within two weeks. This is a brittle and unsafe situation.

Which specific products are affected?

Brand-name and generic verapamil products include Calan, Calan SR, Isoptin SR, Verelan, Verelan PM, and Covera-HS. The interaction applies regardless of immediate-release or extended-release formulation because it is the gut wall enzyme that is induced.

St. John's wort is sold under many brand names and as part of multi-ingredient mood and sleep supplements. Hyperforin content varies widely between products; products standardized to higher hyperforin content (typically 3-5 percent) produce stronger induction. Lower-hyperforin formulations cause less interaction but should still be considered unsafe with verapamil because the variability between batches is large.

The bottom line

St. John's wort and verapamil is one of the best-documented herb-drug interactions in the literature, with verapamil exposure dropping by 78-80 percent. This is a high-severity, clinically meaningful conflict, and the two should not be combined. Always disclose herbal supplement use to your prescriber, and allow at least two weeks of wash-out between stopping St. John's wort and relying on verapamil's full effect.

References

Primary evidence for this article. Always consult your healthcare provider for personal medical advice.

Related Interactions

Other interactions you should know about

Digoxin + St. John's Wort

high

St. John's wort induces intestinal P-glycoprotein, increasing efflux of digoxin and reducing its absorption. Controlled studies show digoxin AUC falls roughly 25% and peak concentrations around 30-36% after two weeks of St. John's wort, potentially producing therapeutic failure in rate control or heart failure management.

Apixaban + St. John's Wort

high

St. John's wort strongly induces both CYP3A4 (apixaban's primary metabolizing enzyme) and P-glycoprotein (its efflux transporter). Co-use accelerates apixaban metabolism and clearance, lowering plasma concentrations and increasing the risk of stroke or thromboembolism.

Simvastatin + St. John's Wort

high

St. John's wort induces intestinal and hepatic CYP3A4 and P-glycoprotein, sharply increasing simvastatin's first-pass metabolism. In a crossover study of healthy adults, the AUC of active simvastatin hydroxy acid was cut roughly in half (to about 48% of placebo).

Dabigatran + St. John's Wort

high

St. John's wort is a potent inducer of P-glycoprotein (P-gp), the efflux transporter responsible for dabigatran disposition. Co-administration increases dabigatran efflux and reduces plasma concentrations, potentially leading to subtherapeutic anticoagulation and increased risk of stroke or thrombosis.

Amlodipine + Grapefruit

low

Amlodipine is a CYP3A4 substrate, but unlike other dihydropyridines (felodipine, nisoldipine), its high oral bioavailability and slow elimination mean grapefruit juice does not meaningfully alter its pharmacokinetics in controlled trials. Some product labels and consumer references still list a theoretical interaction.

Diltiazem + Grapefruit

moderate

Grapefruit juice inhibits intestinal CYP3A4 and increases diltiazem exposure (AUC) by roughly 20% in healthy volunteers, with high inter-individual variability. The increase can amplify the drug's negative chronotropic and hypotensive effects.

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before making changes to your supplement or medication routine. Pilora does not diagnose, treat, cure, or prevent any disease.

Check all your supplement interactions instantly

Try Pilora Free